This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
List view / Grid view
Filter the results
13 May 2015 | By Victoria White
The treatment market value for fibromyalgia across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting…
Pfizer reports top-line results from a Phase 3 study evaluating pregabalin controlled-release formulation as a treatment for patients with postherpetic neuralgia
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release as treatment for patients with fibromyalgia
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation as adjunctive treatment in adult patients with partial onset seizures
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
19 July 2012 | By Pfizer
“The Court’s decision recognizes the infringement & validity of our LYRICA® patents..."
6 July 2012 | By Eli Lilly and Company
Eli Lilly and Company has met the United States FDA requirements for pediatric exclusivity for Cymbalta®...
Pfizer exploratory study measures effects of Lyrica (pregabalin) on brain activity in fibromyalgia patients
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
Pfizer stops Phase 3 trial Of Lyrica (pregabalin) capsules CV in neuropathic pain associated with HIV neuropathy
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
Pfizer reports top-line results from Phase 3 trial of Lyrica (pregabalin) capsules CV in patients with inadequately treated painful diabetic peripheral neuropathy
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
Positive top-line results for Pfizer’s Lyrica in Phase 3 Study of patients with Fibromyalgia in Japan
5 July 2011 | By Pfizer
Pfizer Japan announced the top-line results for Lyrica (pregabalin) Study A0081208...